AI-Driven Blood Test Shows Success in Early Liver Cancer Detection Across Populations
Researchers validate an AI-powered cfDNA blood test that detects liver cancer accurately across diverse populations, enhancing early detection efforts.
Key Details
- 1The DELFI liquid biopsy platform uses cfDNA fragmentome analysis with AI to detect liver cancer.
- 2Validated on 377 participants from Guatemala and Romania with varying liver cancer causes (viral, metabolic, aflatoxin).
- 3Test performed consistently well across distinct genetic and environmental backgrounds.
- 4Combined with AFP and clinical risk factors, it outperformed standard blood tests for early and late-stage disease.
- 5MethID technology traced DNA fragment origins, showing signals not just from tumors but also liver, blood vessel, and immune cells.
- 6DELFI Diagnostics received funding, and several inventors have patents and equity ties to relevant companies.
Why It Matters

Source
EurekAlert
Related News

AI Pathology Tool SÉMIL Improves Stage II Bowel Cancer Risk Assessment
A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.

AI Tool Predicts Which Rectal Cancer Patients Benefit from Intensive Therapy
UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.

AI-Guided Handheld Cardiac Ultrasound Reduces Referrals and Costs in Spain
AI-guided handheld cardiac ultrasound enables primary care physicians to detect heart failure, reducing specialist referrals and saving costs.